No benefit of iron chelation in haemorrhagic stroke
Trials for treatments for intracerebral bleeds may need to be extended to six months
The use of the iron chelator, deferoxamine mesylate, in patients with intracerebral haemorrhage is unlikely to bring benefit by 90 days, but six-month trials may show it has a positive impact on recovery, a US study suggests.
The results of the phase 2 clinical trial (i-DEF) in 283 adult patients have thrown researchers into a quandary, according to Australian neurologist and epidemiologist Professor Craig Anderson, of the George Institute of Global Health at UNSW.
